Using lessons from breast, cervical, and colorectal cancer screening to inform the development of lung cancer screening programs

Cancer

Volumn 122, Issue 9, 2016, Pages 1338-1342

  Armstrong, Katrina ^a   Kim, Jane J ^b   Halm, Ethan A ^c   Ballard, Rachel M ^d   Schnall, Mitchell D ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

implementation; lung cancer; primary care; quality; screening

Indexed keywords

BIOLOGY; BREAST CANCER; CANCER CENTER; CANCER SCREENING; CANCER THERAPY; CLINICAL EVALUATION; COLORECTAL CANCER; FOLLOW UP; HUMAN; LUNG CANCER; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; STANDARD; UTERINE CERVIX CANCER; ADVERSE EFFECTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; CONSENSUS; EARLY CANCER DIAGNOSIS; FEMALE; GENETIC PREDISPOSITION; HEALTH SERVICE; INFORMATION DISSEMINATION; LUNG NEOPLASMS; MALE; MASS SCREENING; ORGANIZATION AND MANAGEMENT; PREVENTION AND CONTROL; PROCEDURES; PROGRAM DEVELOPMENT; SMOKING; STANDARDS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; X-RAY COMPUTED TOMOGRAPHY;

BREAST NEOPLASMS; COLORECTAL NEOPLASMS; CONSENSUS; EARLY DETECTION OF CANCER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFORMATION DISSEMINATION; LUNG NEOPLASMS; MALE; MASS SCREENING; MEDICAL OVERUSE; PRIMARY PREVENTION; PROGRAM DEVELOPMENT; SMOKING; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 84959289977     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29937     Document Type: Review

References (32)

1. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al., Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395-409.
2. Moyer VA,; US Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160: 330-338.
3. Wiener RS, Gould MK, Arenberg DA, et al,; ATS/ACCP Committee on Low-Dose CT Lung Cancer Screening in Clinical Practice. An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice. Am J Respir Crit Care Med. 2015; 192: 881-891.
4. Wender R, Fontham ET, Barrera E Jr, et al., American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013; 63: 107-117.
5. Eberth JM, Sercy E,. Implementation of lung cancer screening in the United States: changing trends based on a survey of Society of Thoracic Radiology members. J Thorac Imaging. 2015; 30: W60-W62.
6. Beaber EF, Kim JJ, Schapira MM, et al,; Population-based Research Optimizing Screening through Personalized Regimens Consortium. Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. J Natl Cancer Inst. 2015; 107: djv120.
7. American College of Radiology. Legislative issues, 2014. http://www.acr.org/advocacy/legislative-issues. Accessed January 7, 2014.
8. Kazerooni EA, Armstrong MR, Amorosa JK, et al., ACR CT accreditation program and the lung cancer screening program designation. J Am Coll Radiol. 2015; 12: 38-42.
9. Centers for Medicare & Medicaid Services, Center for Clinical Standards and Quality. Decision Memo for Screening for Lung Cancer with Low Dose Computed Tomography (LDCT). Baltimore, MD: Centers for Medicare & Medicaid Services, Center for Clinical Standards and Quality; 2015.
10. Solomon D, Davey D, Kurman R, et al,; Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002; 287: 2114-2119.
11. Liberman L, Menell JH,. Breast imaging reporting and data system (BI-RADS). Radiol Clin North Am. 2002; 40: 409-430, v.
12. American College of Radiology. Lung CT Screening Reporting and Data System (Lung-RADS™). http://www.acr.org/Quality-Safety/Resources/LungRADS. Accessed November 18, 2015.
13. Lieberman D, Nadel M, Smith RA, et al., Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc. 2007; 65: 757-766.
14. Jamal A, Homa DM, O'Connor E, et al., Current cigarette smoking among adults-United States, 2005-2014. MMWR Morb Mortal Wkly Rep. 2015; 64: 1233-1240.
15. French C, True S, McIntyre R, Sciulli M, Maloy KA,. State implementation of the Breast and Cervical Cancer Prevention and Treatment Act of 2000: a collaborative effort among government agencies. Public Health Rep. 2004; 119: 279-285.
16. Kushi LH, Doyle C, McCullough M, et al,; American Cancer Society 2010 Nutrition and Physical Activity Guidelines Advisory Committee. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin. 2012; 62: 30-67.
17. Rigotti NA, Quinn VP, Stevens VJ, et al., Tobacco-control policies in 11 leading managed care organizations: progress and challenges. Eff Clin Pract. 2002; 5: 130-136.
18. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW,. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998; 338: 1089-1096.
19. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S,. Human papillomavirus and cervical cancer. Lancet. 2007; 370: 890-907.
20. Bleyer A, Welch HG,. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 2013; 367: 1998-2005.
21. Holowaty P, Miller AB, Rohan T, To T,. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999; 91: 252-258.
22. Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V,. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med. 2010; 170: 977-985.
23. Goodwin JS, Singh A, Reddy N, Riall TS, Kuo YF,. Overuse of screening colonoscopy in the Medicare population. Arch Intern Med. 2011; 171: 1335-1343.
24. Lee SJ, Boscardin WJ, Stijacic-Cenzer I, Conell-Price J, O'Brien S, Walter LC,. Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark. BMJ. 2013; 346: e8441.
25. Patz EF Jr, Pinsky P, Gatsonis C, et al,; NLST Overdiagnosis Manuscript Writing Team. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2014; 174: 269-274.
26. Robson ME, Bradbury AR, Arun B, et al., American Society of Clinical Oncology Policy Statement Update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2015; 33: 3660-3667.
27. Buettner R, Wolf J, Thomas RK,. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol. 2013; 31: 1858-1865.
28. Nakachi I, Rice JL, Coldren CD, et al., Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions. Cancer Prev Res (Phila). 2014; 7: 255-265.
29. Gustafson AM, Soldi R, Anderlind C, et al., Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med. 2010; 2: 26ra25.
30. Ooi AT, Gower AC, Zhang KX, et al., Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res (Phila). 2014; 7: 487-495.
31. Izumchenko E, Chang X, Brait M, et al., Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nat Commun. 2015; 6: 8258.
32. Kensler TW, Spira A, Garber JE, et al., Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prev Res (Phila). 2016; 9: 2-10.